Medications
Ozempic, Zepbound
Monthly Cost
$99-$199
Speed to Start
Moderate
Trustpilot
Not yet rated
FDA-Approved Meds
Est. 2020
About G-Plans
G-Plans was founded in 2020 and has carved out a distinctive niche in the GLP-1 telehealth landscape by combining brand-name medication prescribing with AI-powered meal planning and optional prepared meal delivery. The platform prescribes Ozempic (semaglutide) and Zepbound (tirzepatide) — both FDA-approved brand-name medications — at monthly costs ranging from $99 to $199 for the platform fee, with medication costs handled separately through insurance or pharmacy pricing. This hybrid model of pharmaceutical access plus nutritional technology aims to address the common criticism that GLP-1 programs neglect the dietary side of weight management.
The AI meal planning system is G-Plans’ signature feature. After completing a metabolic assessment, patients receive personalized meal plans generated by the platform’s algorithm, which accounts for dietary preferences, caloric targets, and macronutrient ratios. For patients who want the convenience factor taken further, G-Plans offers optional meal delivery through partner services. The platform also provides access to a registered dietitian for consultations, and the overall support level is high relative to its price point, with regular check-ins and nutritional guidance built into the program.
However, G-Plans carries an F rating with the Better Business Bureau — the lowest grade available — which is a significant concern that prospective patients must weigh carefully. BBB ratings reflect factors including complaint volume, complaint resolution, and business transparency. An F rating typically indicates a pattern of unresolved consumer complaints or failure to respond to the BBB’s inquiries. Our editorial team strongly recommends that patients research the nature of these complaints before enrolling and document all communications and billing agreements with the platform.
G-Plans does not have a Trustpilot profile, and the platform does not accept insurance for its program fees, though patients may be able to use insurance for the brand-name medications themselves through their pharmacy. The lack of independent consumer review data combined with the F BBB rating creates a transparency gap that is difficult to overlook. The clinical model — brand-name medications, dietitian access, AI meal planning — is genuinely innovative, but the business practices reflected in the BBB rating introduce risk that patients should carefully evaluate.
G-Plans represents an intriguing concept with execution concerns. The combination of brand-name GLP-1 medications, AI-driven nutrition planning, and meal delivery addresses real gaps in the telehealth weight loss market. The dietitian access and high support level add clinical credibility. But the F BBB rating casts a shadow over the patient experience, and the absence of insurance acceptance and independent reviews makes it harder to recommend without reservation. Patients drawn to G-Plans’ unique features should proceed with due diligence, clear billing documentation, and realistic expectations about customer service.
G-Plans GLP-1 Medications
At a Glance
Medications Offered
Ozempic, Zepbound
Brand-Name
Cost & Insurance
- Monthly: $99-$199
- 6-month estimate: $594-$1,194
- Insurance: No
- Self-pay: Yes
Clinical Features
- Lab testing: No
- Dietitian access: Yes
- Verified Pharmacy: N/A — Brand-name only (Ozempic, Zepbound)
- BBB Rating: F
Delivery & Access
- Format: Subcutaneous
- Nationwide telehealth: Yes
- Speed: Moderate
- Spanish-speaking providers: Not available
What the G-Plans Intake Looks Like
G-Plans operates a hybrid GLP-1 + nutrition-coaching model. We walked the full intake on April 29, 2026 and came away with two opposing observations: the disqualifier and vital-sign rigor is among the strongest in our catalog, but a notable gap stands out — neither MTC nor MEN-2 is named explicitly anywhere in the funnel, despite extensive coverage of nearly every other FDA-black-box and metabolic risk factor.
Among the strongest in our catalog. Eating disorder named, suicidality named, postpartum window asked, opiate-use within last 3 months, blood pressure tiered to AHA staging, resting heart rate tiered, T1D vs T2D-on-insulin vs T2D-not-on-insulin distinguished, and deep nutrition profiling. The deduction is one specific gap: MTC and MEN-2 are not named anywhere despite the intake naming pancreatitis, eating disorder, and postpartum status explicitly.
High. 30 screens, three marketing interstitials sprinkled throughout, deep nutrition-profiling block (dietary preferences + food allergies + carbohydrate sources + protein sources + pace) that most pure-GLP-1 funnels skip, and a fake-urgency “Your approval is reserved for 14:44” countdown timer at the pricing screen. Pricing is $129/month or $99/month In Full ($594 paid upfront, save 30%). Account-creation comes late — after all clinical questions.
The 15 Stages
Clinical Safety Screens Performed
Most cash-pay GLP-1 funnels either skip blood pressure entirely or ask a single threshold yes/no (“Is your BP above 140/90?”). G-Plans asks for the patient’s BP range across four tiers that match the American Heart Association’s hypertension staging exactly — Normal (<120/80), Elevated (120-129/<80), High Stage 1 (130-139/80-89), High Stage 2 (≥140/90). Resting heart rate is similarly tiered. Tiered vital-sign capture is uncommon outside in-person clinical intake forms and is a meaningful upgrade over yes/no thresholds for downstream clinician review.
Like Shed and unlike most platforms in our catalog, G-Plans waits until screen 27 — after all clinical screening AND nutrition profiling — to ask the patient to create an account. The patient walks the entire questionnaire anonymously. This pattern treats the medical questionnaire as the qualifier and the account as the persistence layer once the patient is approved, rather than gating clinical questions behind a lead-capture form.
The notable gap in G-Plans’ otherwise comprehensive screen is the FDA-black-box thyroid screening. Pancreatitis is named explicitly as a current-or-history condition. Eating disorder is named. Suicidality is named. Postpartum window is named. But neither medullary thyroid cancer (MTC) nor multiple endocrine neoplasia syndrome type 2 (MEN-2) appears anywhere in the funnel — neither as a condition checkbox nor as a family-history question. For a platform that names so many other clinical specifics correctly, this is a meaningful omission. Patients with personal or family history of MTC or MEN-2 should disclose this in the free-text “is there any further information for the doctor” field on screen 19.
After the qualification screen, G-Plans displays a banner reading “YOUR APPROVAL EXPIRES IN 14:54” with a live countdown. Like Zealthy’s similar timer (which we documented previously), the label is misleading — no licensed clinician has reviewed the patient at the moment the timer starts; the “approval” being timed-out is the discount price, not a clinical decision. We flag this as a dark-pattern checkout pressure tactic that is at odds with the otherwise clinically rigorous screening.
No MTC, no MEN-2 (named gap above). No family history capture beyond the conditions multi-selects (no “anyone in your family had…” style questions). No alcohol or tobacco/nicotine screen — opiate use is asked but the more common substances are not. No validated PHQ-2/PHQ-9 — suicidality is asked as a yes/no in the contraindication multi-select, not as a scored instrument. No phone OTP, no government ID upload. The intake’s strengths are clearly on the disqualifier and vital-sign side; the gaps cluster in family history and substance use beyond opiates.
Source: GLP-1.Reviews editorial walkthrough on April 29, 2026. We completed every screen of the G-Plans intake using a representative GLP-1 candidate persona and stopped before submitting the $99 In Full or $129 Monthly checkout payment.
Opens gplans.com in a new tab. We may earn a commission if you start treatment through this link, at no additional cost to you.
Start your GLP-1 weight loss journey with G-Plans today
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.
Editorial Independence: GLP-1.Reviews maintains full editorial independence. Our scores are based on verified data and standardized criteria.
